Department of Biochemistry and Molecular Biology, Tulane University School of Medicine, New Orleans, LA 70112, USA.
Department of Pathology, Tulane University School of Medicine, New Orleans, LA 70112, USA; Tulane Cancer Center, Tulane University School of Medicine, 1430 Tulane Ave., New Orleans, LA 70112, USA.
Mol Cell. 2020 Jun 18;78(6):1166-1177.e6. doi: 10.1016/j.molcel.2020.05.012. Epub 2020 Jun 3.
Human tumors with exonuclease domain mutations in the gene encoding DNA polymerase ε (POLE) have incredibly high mutation burdens. These errors arise in four unique mutation signatures occurring in different relative amounts, the etiologies of which remain poorly understood. We used CRISPR-Cas9 to engineer human cell lines expressing POLE tumor variants, with and without mismatch repair (MMR). Whole-exome sequencing of these cells after defined numbers of population doublings permitted analysis of nascent mutation accumulation. Unlike an exonuclease active site mutant that we previously characterized, POLE cancer mutants readily drive signature mutagenesis in the presence of functional MMR. Comparison of cell line and human patient data suggests that the relative abundance of mutation signatures partitions POLE tumors into distinct subgroups dependent on the nature of the POLE allele, its expression level, and MMR status. These results suggest that different POLE mutants have previously unappreciated differences in replication fidelity and mutagenesis.
具有编码 DNA 聚合酶 ε(POLE)基因中外切酶结构域突变的人类肿瘤具有极高的突变负担。这些错误出现在以不同相对量发生的四个独特的突变特征中,其病因仍知之甚少。我们使用 CRISPR-Cas9 工程化表达 POLE 肿瘤变体的人类细胞系,有和没有错配修复(MMR)。在经过定义数量的群体倍增后,对这些细胞进行全外显子组测序,允许分析新出现的突变积累。与我们之前表征的具有外切酶活性位点突变的细胞不同,POLE 癌症突变体在功能 MMR 存在下容易驱动特征性诱变。细胞系和人类患者数据的比较表明,突变特征的相对丰度将 POLE 肿瘤分为不同的亚组,这取决于 POLE 等位基因的性质、其表达水平和 MMR 状态。这些结果表明,不同的 POLE 突变体在复制保真度和诱变方面具有以前未被认识到的差异。